Bicycle therapeutics plc (BCYC)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19
Cash flows from operating activities:
Net loss

-11,324

-4,406

-9,482

-10,217

-6,503

Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense

2,121

1,083

819

905

276

Depreciation and amortization

305

274

243

230

213

Change in fair value of warrant liability

0

0

0

2,184

3,197

Changes in operating assets and liabilities:
Accounts receivable

846

155

-109

-95

-4,860

Research and development incentives receivable

2,097

-4,430

1,295

1,868

1,650

Prepaid expenses and other current assets

-347

1,085

1,578

-155

215

Operating lease right-of-use assets

-187

-184

-176

-176

-176

Other assets

215

181

92

249

-125

Accounts payable

2,702

-296

-14

115

415

Accrued expenses and other current liabilities

-464

-241

367

-195

-783

Lease liabilities

191

-183

-175

-175

-176

Deferred revenue

30,103

-4,793

-173

998

-5,327

Other long-term liabilities

152

450

210

238

191

Net cash provided by (used in) operating activities

21,162

-4,919

-10,885

-7,608

-5,201

Cash used in investing activities:
Purchases of property and equipment

320

391

283

463

418

Net cash used in investing activities

-320

-391

-283

-463

-418

Cash flows from financing activities:
Payments of initial public offering costs

-

-

-

-

1,300

Proceeds from the exercise of share options and sale of ordinary shares

2

-

-

-

-

Net cash provided by financing activities

2

122

-811

59,095

34

Effect of exchange rate changes on cash

-3,324

1,351

-603

-1,852

1,569

Net increase (decrease) in cash

17,520

-3,837

-12,582

49,172

-4,016

Supplemental disclosure of cash flow information
Cash paid for income taxes

11

-

-

-

-

Cash paid for amounts included in the measurement of operating lease liabilities

-

444

0

223

224

Purchases of property and equipment included in accounts payable and accrued expenses

71

-

-

-

-

Deferred initial public offering costs accrued but not paid

-

-

-

-

431

Series B2 Convertible Preferred Shares
Proceeds from issuance of convertible preferred shares, net of issuance costs

-

-

-

-

1,334